Born in 2020 from a strategic alliance between Noxopharm Ltd and Hudson Institute of Medical Research (HIMR), Pharmorage aims at discovering and developing next generation anti-inflammatory drugs to treat diseases resulting from aberrant inflammation. To fulfil our mission, we leverage two proprietary innovative platforms based on small molecules and synthetic RNAs technologies.